Market Cap 1.99B
Revenue (ttm) 63.72M
Net Income (ttm) -193.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -303.69%
Debt to Equity Ratio 0.23
Volume 1,658,300
Avg Vol 2,851,416
Day's Range N/A - N/A
Shares Out 174.00M
Stochastic %K 32%
Beta 1.45
Analysts Strong Sell
Price Target $21.00

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Fax: 781 275 7562
Address:
15 Crosby Drive, Bedford, United States
Harvo
Harvo Oct. 25 at 12:26 PM
$OCUL What does Lilly know? Have they figured out how to make AAV's safe in the eye?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 1:52 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $OCUL Current Share Price: $11.35 Contracts: $OCUL January 15, 2027 $12 Calls Scale in: $3.80- $4.65 Scale out: $5.91-$7.60 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
SmokenTuna
SmokenTuna Oct. 24 at 2:15 PM
$OCUL I miss the days when we ran into the teens for no reason.
0 · Reply
ergiamel
ergiamel Oct. 23 at 6:32 PM
$OCUL glad we have the same dates! Under listing rules, do they not have 4 days to report a significant event?
1 · Reply
betonthenews
betonthenews Oct. 23 at 5:17 PM
$OCUL SOL-1 36 weeks' primary end point for superiority has ended on Aug 15, and 52 masked weeks' redosing ends on Dec 5, first week of DEC. Very likely CRO is doing the data base cleaning and scrubbing real time as patients goes through the 52 weeks' redosing now, should be 95-98% ready for data base lock by DEC 5, the last SOL-1 patient redosing done, by the time the JPM 2026 health conference on Jan 12-15, CRO has 5 weeks to get the topline ready, SOL-1 only has 1 primary efficacy endpoint, so it is relatively simple data base to do analysis and fast to get the topline out, my guess is CEO wants to showcase the topline data on OCUL's JPM conference presentation.
0 · Reply
Fairvalue10
Fairvalue10 Oct. 23 at 12:35 PM
$OCUL Wrong Board. Sorry
0 · Reply
Fairvalue10
Fairvalue10 Oct. 23 at 8:11 AM
$OCUL The quiet departure of Will Dolan, SVP Strategy & Business Development, just before the 25 % workforce reduction, strongly suggests a buyout scenario rather than a partnership. In a partnership, he would have remained to structure and execute the deal, whereas his exit — combined with the unusual appointment of two Co-CEOs from Legal and Finance points to a transaction already in its final stage of execution. As one observer noted, “you don’t replace your CEO with lawyers and a CFO unless the paperwork is nearly done.” patience
1 · Reply
rizzato
rizzato Oct. 22 at 4:07 PM
$OCUL they continue to reiterate buy on both company and we continue to drop what I'm loosing on the history
0 · Reply
SmokenTuna
SmokenTuna Oct. 22 at 3:42 PM
$OCUL I hope we get a rally into p3 but I’m not holding my breath. It’s a show me evidence first.
3 · Reply
rizzato
rizzato Oct. 22 at 1:52 PM
$OCUL again also today both oculus and eypt red or flat , what happen ?
0 · Reply
Latest News on OCUL
Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 10:16 AM EST - 8 months ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript


Ocular Is Now Thoroughly Derisked

Dec 30, 2024, 12:16 PM EST - 10 months ago

Ocular Is Now Thoroughly Derisked


Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results


Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024


Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results


Harvo
Harvo Oct. 25 at 12:26 PM
$OCUL What does Lilly know? Have they figured out how to make AAV's safe in the eye?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 1:52 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $OCUL Current Share Price: $11.35 Contracts: $OCUL January 15, 2027 $12 Calls Scale in: $3.80- $4.65 Scale out: $5.91-$7.60 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
SmokenTuna
SmokenTuna Oct. 24 at 2:15 PM
$OCUL I miss the days when we ran into the teens for no reason.
0 · Reply
ergiamel
ergiamel Oct. 23 at 6:32 PM
$OCUL glad we have the same dates! Under listing rules, do they not have 4 days to report a significant event?
1 · Reply
betonthenews
betonthenews Oct. 23 at 5:17 PM
$OCUL SOL-1 36 weeks' primary end point for superiority has ended on Aug 15, and 52 masked weeks' redosing ends on Dec 5, first week of DEC. Very likely CRO is doing the data base cleaning and scrubbing real time as patients goes through the 52 weeks' redosing now, should be 95-98% ready for data base lock by DEC 5, the last SOL-1 patient redosing done, by the time the JPM 2026 health conference on Jan 12-15, CRO has 5 weeks to get the topline ready, SOL-1 only has 1 primary efficacy endpoint, so it is relatively simple data base to do analysis and fast to get the topline out, my guess is CEO wants to showcase the topline data on OCUL's JPM conference presentation.
0 · Reply
Fairvalue10
Fairvalue10 Oct. 23 at 12:35 PM
$OCUL Wrong Board. Sorry
0 · Reply
Fairvalue10
Fairvalue10 Oct. 23 at 8:11 AM
$OCUL The quiet departure of Will Dolan, SVP Strategy & Business Development, just before the 25 % workforce reduction, strongly suggests a buyout scenario rather than a partnership. In a partnership, he would have remained to structure and execute the deal, whereas his exit — combined with the unusual appointment of two Co-CEOs from Legal and Finance points to a transaction already in its final stage of execution. As one observer noted, “you don’t replace your CEO with lawyers and a CFO unless the paperwork is nearly done.” patience
1 · Reply
rizzato
rizzato Oct. 22 at 4:07 PM
$OCUL they continue to reiterate buy on both company and we continue to drop what I'm loosing on the history
0 · Reply
SmokenTuna
SmokenTuna Oct. 22 at 3:42 PM
$OCUL I hope we get a rally into p3 but I’m not holding my breath. It’s a show me evidence first.
3 · Reply
rizzato
rizzato Oct. 22 at 1:52 PM
$OCUL again also today both oculus and eypt red or flat , what happen ?
0 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Oct. 21 at 8:55 PM
$OCUL AI analysis...“OCUL is digesting dilution in a healthy, constructive wedge; poised for resolution soon, with bias to the upside if the $12.80 zone clears with conviction.” Breakout likely to happen when they announce the start of P3's for NPDR.... Target $14.5 - $15.
0 · Reply
Tmoney85285
Tmoney85285 Oct. 21 at 3:41 PM
$OCUL it's been 3 weeks, wonder why they haven't raised more money at this point! LOL
0 · Reply
Quantumup
Quantumup Oct. 21 at 2:34 PM
RBC Capital reiterated $FDMT Outperform-$26, and said Boston NDR Strengthens Its Conviction That GTx Will Have a Role in the $15B Retina Market $OCUL $EYPT $REGN KOD $RGNX - ABBV ADVM SNY RBC Capital additionally said:
1 · Reply
The_Fact_ster
The_Fact_ster Oct. 21 at 2:20 PM
$OCUL so if this comes down to 10, the question is do I buy a little bit more or a lotta bit more?
1 · Reply
rizzato
rizzato Oct. 21 at 1:52 PM
$OCUL is there any connection between the oculus red and the eypt red? any idea?
0 · Reply
Fairvalue10
Fairvalue10 Oct. 21 at 7:30 AM
$OCUL Only 3 shares traded @11.72 …. After hours
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 11:56 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $OCUL Current Share Price: $11.84 Contracts: $OCUL January 15, 2027 $12 Calls Scale in: $3.78- $4.62 Scale out: $5.88-$7.56 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
SmokenTuna
SmokenTuna Oct. 19 at 12:05 AM
$OCUL saw this and on x. Interesting if we can get in on this or even DR. https://duckduckgo.com/?q=cnpv+fda&ia=web
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 2:57 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $OCUL Current Share Price: $12.20 Contracts: $OCUL January 15, 2027 $15 Calls Scale in: $3.32- $4.06 Scale out: $5.17-$6.64 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Fairvalue10
Fairvalue10 Oct. 17 at 11:13 PM
$OCUL @Aaronpell To reply to your message in which you mentioned that after-hours trading is meaningless and not important, I completely understand your point of view as a highly knowledgeable expert — and, of course, as a sharp analyst. It’s just that when the average after-hours trading volume jumps from around 21,220 shares over the past two years to more than 400,000 for ten consecutive sessions — even with a sizable shelf offering — some of us can’t help but find that a little intriguing. I perfectly understand that, from your elevated standpoint, such things might appear irrelevant. But for those of us who are perhaps a bit less brilliant, yet still fairly familiar with how biotech names behave, it’s rather hard not to notice.
1 · Reply
SmokenTuna
SmokenTuna Oct. 17 at 3:02 PM
$OCUL they’re really screwing with us.,
1 · Reply
rizzato
rizzato Oct. 17 at 3:02 PM
$OCUL any idea why we are dropping so deep today?
1 · Reply